Cited by 81Transcranial Magnetic Stimulation StudiesElectroconvulsive Therapy StudiesTreatment of Major Depression

A randomized sham controlled comparison of once vs twice-daily intermittent theta burst stimulation in depression: A Canadian rTMS treatment and biomarker network in depression (CARTBIND) study

Open access
Blumberger, Daniel M., Vila-Rodriguez, Fidel, Wang, Wei, Knyahnytska, Yuliya, Butterfield, Michael, Noda, Yoshihiro, Yariv, Shahak, Isserles, Moshe +6 more·2021·Brain Stimulation

Abstract

BACKGROUND: Intermittent theta burst stimulation (iTBS) is a newer form of repetitive transcranial magnetic stimulation (rTMS) for patients with treatment resistant depression (TRD). Applying multiple daily iTBS sessions may enable patients to achieve remission more rapidly. OBJECTIVE: We compared the efficacy and tolerability of a twice-daily versus once-daily iTBS protocol in patients with TRD. We hypothesized that twice-daily iTBS would result in a greater improvement in depression scores compared to once-daily iTBS. METHODS: 208 participants (131 females) with TRD were randomized to receive either iTBS (600 pulses) delivered twice-daily with a 54-min interval between treatments or once-daily (1200 pulses) with 1 sham treatment with the same interval between treatments, to ensure equal levels of daily therapeutic contact and blinding of patients and raters. The primary outcome measure was change in depression scores on the Hamilton Rating Scale for Depression (HRSD-17) after 10 days of treatment and 30 days of treatments. RESULTS: HRSD-17 scores improved in both the twice-daily and once-daily iTBS groups; however, these improvements did not significantly differ between the two groups at either the 10-day or 30-day timepoints. Response and remission rates were low (<10%) in both groups after 10 days and consistent with prior reports at 30 days; these rates did not differ between the treatment groups. CONCLUSIONS: These results suggest that twice-daily iTBS does not accelerate response to iTBS and is not different from once-daily treatment in terms of improving depressive symptoms in patients with TRD. Clinicaltrials.gov ID: NCT02729792 (https://clinicaltrials.gov/ct2/show/NCT02729792).

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.brs.2021.09.003

Cites

29 of 29 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Numerous studies of TBS for TRD have been published, but studies tend to report reduction in depressive symptoms as the sole outcome measure, focus on neuroimaging, or report other clinical outcomes.

    “Numerous studies of TBS for TRD have been published, but studies tend to report reduction in depressive symptoms as the sole outcome measure (e.g., Bakker et al., 2015;Blumberger et al., 2018;Blumberger et al., 2021;Bouaziz et al., 2023;Bulteau et al., 2022;Caeyenberghs et al., 2018;Chen et al., 2021;Lee et al., 2021;Mehta et al., 2022;Spitz et al., 2022;Spurny-Dworak et al., 2022;Stöhrmann et al.”

    From Neurocognitive effects of theta burst stimulation for treatment-resistant depression in adults: A systematic review and recommendations for future research (2025) · cites this paper as Blumberger et al., 2021

    The Results (§3.1) report reduced depressive-symptom scores in both treatment groups, so this paper supports that part of the citation. But the Procedures (§2.2) also identify adverse events, pain intensity, serious adverse events, and treatment discontinuation as reported outcomes; depressive symptoms were not the sole outcome measure. Page numbers were not available in our copy. (LLM, conf=0.87)

    Experimental — accuracy not yet measured

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Part of this paper’s reference list could not be split into single entries.

Flagged first, then by citations

1 of the 30 references couldn’t be matched to a known paper.

Research works printed but not linked: 1

  1. [25]25. Beck, A.T. ∙ Steer, R.A. ∙ Brown, G.K. Beck depression Inventory-second Edition manual The Psychological Corporation, San Antonio, TX, 1996 Google Scholar

Cited by

Sorted by citations

Authors
Blumberger, D. M., Vila-Rodriguez, F., Wang, W., Knyahnytska, Y., Butterfield, M., Noda, Y., Yariv, S., Isserles, M., Voineskos, D., Ainsworth, N. J., Kennedy, S. H., Lam, R. W., Daskalakis, Z. J., & Downar, J.
Affiliations
  • Centre for Addiction and Mental Health (CA)
  • University of British Columbia (CA)
  • Keio University (JP)
  • Technion – Israel Institute of Technology (IL)
  • Jerusalem Mental Health Center (IL)
  • St. Michael's Hospital (CA)
  • University of California San Diego (US)
  • University Health Network (CA)
Corresponding author
Blumberger, Daniel M.
Venue
Brain Stimulation
Publisher
Elsevier BV
Published
2021-11
Volume
14
Issue
6
Pages
1447-1455
ISSN
  • 1876-4754 (ISSN-L)
  • 1935-861X
OpenAlex
W3200522299
Cited by
81
References
30
Citations by year
2026: 20 · 2025: 20 · 2024: 13 · 2023: 15 · 2022: 12 · 2021: 1
FWCI
4.10
Type
journal article
Language
en
Open access
Locations
  • Brain stimulation (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Funders
  • Toronto General and Western Hospital Foundation
  • Health Canada
  • Family Care Foundation
  • Arrell Family Foundation
  • Fondation Brain Canada
Topics
  • Life Sciences › Neuroscience › Neurology › Transcranial Magnetic Stimulation Studies
  • Health Sciences › Medicine › Psychiatry and Mental health › Electroconvulsive Therapy Studies
  • Health Sciences › Medicine › Pharmacology › Treatment of Major Depression
Keywords
intermittent theta burst stimulation, treatment-resistant depression, repetitive transcranial magnetic stimulation, treatment response and remission
MeSH terms
Canada, Depression, Female, Humans, Biomarkers, Treatment Outcome, Prefrontal Cortex, Transcranial Magnetic Stimulation

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review